MedTrace Logo

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

NCT00038246 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-10-31

No results posted yet for this study

Summary

The three study drugs (Thalidomide, Taxol, and Estramustine) used in this study are all chemotherapy drugs used in shrinking the cancer.

Conditions

Interventions

DRUG

Estramustine

140 mg by mouth (po) three times a day on Days 1-5, 8-12

DRUG

Thalidomide

200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.

DRUG

Paclitaxel (Taxol)

100 mg/m\^2 by vein (IV) over 3 hours Day 3 and Day 10

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Christopher J. Logothetis, MD · UT MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-31
Primary Completion
2004-02-29
Completion
2004-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00038246 on ClinicalTrials.gov